☆ 4.6 Review

Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes

DRUGS (2023)

Related references

Note: Only part of the references are listed.

Article Behavioral Sciences

Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: A critical period for early neurodevelopment

Kim I. Bishop et al.

Summary: This study aimed to evaluate the association between fenfluramine (FFA) and improvement in everyday executive function (EF) in preschool-aged children with Dravet syndrome (DS). The results showed that the FFA treatment group demonstrated reliable and clinically meaningful improvement in self-control, flexibility, metacognition, and overall executive function. Among the FFA treatment groups, the 0.7 mg/kg/day dosage group showed the most significant improvement.

EPILEPSY & BEHAVIOR (2023)

Add to Collection

Article Clinical Neurology

Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study

Kelly G. Knupp et al.

Summary: Long-term use of fenfluramine showed sustained reduction in drop seizure frequency in LGS patients, with significant reduction in the frequency of GTCS and tonic seizures. The drug was generally well tolerated with minimal adverse effects and no significant cardiac side effects observed. Fenfluramine may serve as an important long-term treatment option for patients with LGS.

EPILEPSIA (2023)

Add to Collection

Review Economics

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Ben Wijnen et al.

Summary: This paper presents the evaluation of the cost-effectiveness of fenfluramine for the treatment of patients with Dravet syndrome. Through the analysis of clinical trials and real-world data, it was proven that fenfluramine is more effective than cannabidiol in terms of reducing convulsive seizure frequency and increasing convulsive seizure-free days. The company's economic model also showed that fenfluramine is more cost-effective than cannabidiol. Ultimately, NICE recommended the use of fenfluramine as an add-on treatment in the National Health Service (NHS) in the UK.

PHARMACOECONOMICS (2023)

Add to Collection

Meeting Abstract Clinical Neurology

Fenfluramine Treatment Is Associated With Improvement in Everyday Executive Function in Adults With Lennox-Gastaut Syndrome: Post-Hoc Analysis of Dose Effects From a Phase 3 Trial Rationale

Kim Bishop et al.

NEUROLOGY (2023)

Add to Collection

Article Clinical Neurology

A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome

An-Sofie Schoonjans et al.

Summary: Dravet Syndrome (DS) is a severe developmental and epileptic encephalopathy, with fenfluramine recently proving to be highly effective and safe in reducing seizure frequency. Although the exact mechanism of action is not fully understood, fenfluramine shows potential in DS treatment beyond its anticonvulsive effect, warranting further research.

EXPERT REVIEW OF NEUROTHERAPEUTICS (2022)

Add to Collection

Article Clinical Neurology

A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication

Adam Strzelczyk et al.

Summary: Dravet syndrome is a severe developmental and epileptic encephalopathy that is difficult to treat. Three adjunct medications have been approved for the treatment of seizures in patients with Dravet syndrome. The choice of medication depends on various factors, including availability, patient characteristics, and caregiver preferences. It is important to consider the potential interactions and side effects of different medications.

CNS DRUGS (2022)

Add to Collection

Article Clinical Neurology

Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: A time-to-event analysis

Joseph Sullivan et al.

Summary: The study demonstrates that adjunctive use of fenfluramine can significantly reduce day-to-day seizure burden in patients with DS, providing prolonged periods of convulsive seizure-free days, which may help reduce the physical and emotional disease toll while improving health-related quality of life for patients and caregivers.

EPILEPSIA (2022)

Add to Collection

Article Clinical Neurology

International consensus on diagnosis and management of Dravet syndrome

Elaine C. Wirrell et al.

Summary: This study aimed to reach a consensus on the diagnosis and management of Dravet syndrome (DS) by consulting experienced physicians and caregivers. The study summarized the current literature and obtained opinions from an expert panel on the diagnosis and management of DS. The results showed that there was consensus on the diagnosis and treatment of DS, but there was disagreement on disease-modifying therapies.

EPILEPSIA (2022)

Add to Collection

Article Clinical Neurology

Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome A Randomized Clinical Trial

Kelly G. Knupp et al.

Summary: The trial demonstrates the efficacy of fenfluramine in reducing drop seizures in patients with Lennox-Gastaut syndrome (LGS) and suggests that it may be particularly beneficial for those experiencing generalized tonic-clonic seizures.

JAMA NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Long-term cardiovascular safety of fenfluramine in patients with Dravet syndrome treated for up to 3 years: Findings from serial echocardiographic assessments

Anupam Agarwal et al.

Summary: The study found no cases of valvular heart disease or pulmonary artery hypertension in patients with Dravet syndrome treated with fenfluramine, supporting a positive benefit-risk profile for the drug in this population.

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Fenfluramine treatment for dravet syndrome: Real-world benefits on quality of life from the caregiver perspective

Mark P. Jensen et al.

Summary: This study found that fenfluramine (FFA) can significantly improve the quality of life for individuals with Dravet syndrome (DS), including reducing seizure activity, improving cognitive function and academic performance, as well as improving caregivers' sleep quality and reducing stress. It also found that FFA treatment can improve the relationships between individuals with DS and their siblings.

EPILEPSY RESEARCH (2022)

Add to Collection

Article Clinical Neurology

An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real-world practice setting: A report from the Fenfluramine European Early Access Program

Renzo Guerrini et al.

Summary: The efficacy and safety of fenfluramine treatment in patients with Dravet syndrome were examined. The results showed that fenfluramine significantly reduced convulsive seizure frequency in all age groups and had no adverse effects on the heart and pulmonary artery hypertension.

EPILEPSIA OPEN (2022)

Add to Collection

Review Clinical Neurology

Serotonin receptors in epilepsy: Novel treatment targets?

Jo Sourbron et al.

Summary: Despite the availability of over 30 antiseizure medications, there is a continuing search for novel drugs. Modulation of serotonin receptors has shown potential in the treatment of epilepsy and comorbidities. The available preclinical and clinical studies emphasize the role of serotonergic modulation as a promising avenue in epilepsy treatment.

EPILEPSIA OPEN (2022)

Add to Collection

Review Clinical Neurology

Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies

Adam Strzelczyk et al.

Summary: Lennox-Gastaut syndrome (LGS) is a childhood-onset seizure disorder with multiple causes and no single genetic origin. It is characterized by multiple seizure types and complex treatment due to its diverse morbidities.

CNS DRUGS (2021)

Add to Collection

Article Clinical Neurology

Fenfluramine responder analyses and numbers needed to treat: Translating epilepsy trial data into clinical practice

Joseph Sullivan et al.

Summary: Clinical trials evaluating the efficacy of antiepileptic drugs in Dravet syndrome patients showed that treatment with fenfluramine can significantly reduce convulsive seizure frequency, with approximately one in every two to three patients achieving meaningful improvements.

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Serotonin 5-HT4 receptors play a critical role in the action of fenfluramine to block seizure-induced sudden death in a mouse model of SUDEP

Srinivasan Tupal et al.

Summary: The study found that the action of fenfluramine in preventing seizure-induced sudden death in mice is primarily mediated by activation of 5-HT4 receptors, with 5-HT1A and 5-HT2 antagonists enhancing its anticonvulsant effects. These findings support the serotonin hypothesis of SUDEP.

EPILEPSY RESEARCH (2021)

Add to Collection

Article Clinical Neurology

Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome

J. Helen Cross et al.

Summary: This study found that the all-cause and SUDEP mortality rates in DS patients treated with FFA were lower than previously reported. Further studies are needed to confirm the impact of FFA on SUDEP risk and to explore the underlying mechanisms.

SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2021)

Add to Collection

Article Clinical Neurology

Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison

Nagita Devi et al.

Summary: This study compared the efficacy and safety of three anti-seizure medications in children with Dravet syndrome and found that stiripentol had the best outcome in reducing seizure frequency and occurrence of adverse events.

SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know

Reem Odi et al.

Summary: Racemic-fenfluramine was approved for the treatment of seizures associated with Dravet syndrome in 2020, showing efficacy in controlling convulsive seizures. Different serotonergic mechanisms are responsible for appetite suppression and cardiac valvulopathy induced by fenfluramine. While early evidence indicates no cardiovascular toxicity in epilepsy patients treated with fenfluramine, more research is needed to fully understand its antiseizure effects and potential risks.

PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Clinical Neurology

Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany

Adam Strzelczyk et al.

Summary: In a large cohort of patients with Dravet syndrome, fenfluramine (FFA) demonstrated efficacy in reducing convulsive seizures and was well tolerated under a compassionate use program in Germany. The responder rates for total seizures and generalized tonic-clonic seizures were consistent at 3, 6, and 12 months. Additionally, a significant reduction in seizure days per month and a decrease in episodes of status epilepticus were observed after FFA treatment.

EPILEPSIA (2021)

Add to Collection

Review Biochemistry & Molecular Biology

An Emerging Role for Sigma-1 Receptors in the Treatment of Developmental and Epileptic Encephalopathies

Parthena Martin et al.

Summary: Recent evidence suggests that sigma-1 receptors may play a role in the pathogenesis of DEEs, with studies demonstrating that fenfluramine, a serotonin-releasing drug and positive modulator of sigma-1 receptors, can reduce seizures and improve everyday executive functions in patients with Dravet syndrome and Lennox-Gastaut syndrome. Opportunities for future research include developing appropriate models to evaluate sigma-1 receptors in these syndromic epileptic conditions.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Efficacy of Fenfluramine and Norfenfluramine Enantiomers and Various Antiepileptic Drugs in a Zebrafish Model of Dravet Syndrome

Jing Li et al.

Summary: Dravet syndrome is a rare genetic encephalopathy characterized by severe seizures, with FDA approval of fenfluramine for treatment. Research suggests that different enantiomers have varying antiepileptic effects, with some showing significant efficacy, contributing to the treatment of DS.

NEUROCHEMICAL RESEARCH (2021)

Add to Collection

Article Economics

PND33 A Cost-Effectiveness Analysis of Fenfluramine for the Treatment of Seizures for Patients with Dravet Syndrome (DS) in the UK Setting

G. Weston et al.

VALUE IN HEALTH (2021)

Add to Collection

Review Clinical Neurology

Changing Landscape of Dravet Syndrome Management: An Overview

Debopam Samanta

NEUROPEDIATRICS (2020)

Add to Collection

Article Clinical Neurology

Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens A Randomized Clinical Trial

Rima Nabbout et al.

JAMA NEUROLOGY (2020)

Add to Collection

Review Neurosciences

Mechanisms of action of currently used antiseizure drugs

Graeme J. Sills et al.

NEUROPHARMACOLOGY (2020)

Add to Collection

Article Clinical Neurology

Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long-term open-label safety extension study

Wyman W. Lai et al.

EPILEPSIA (2020)

Add to Collection

Article Clinical Neurology

Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real-world study

Nicola Specchio et al.

EPILEPSIA (2020)

Add to Collection

Article Clinical Neurology

Fenfluramine HCl (Fintepla(R)) provides long-term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open-label extension study

Joseph Sullivan et al.

EPILEPSIA (2020)

Add to Collection

Article Pharmacology & Pharmacy

A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects

Brooks Boyd et al.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2019)

Add to Collection

Article Medicine, General & Internal

Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial

Lieven Lagae et al.

LANCET (2019)

Add to Collection

Article Pharmacology & Pharmacy

The Lack of Effect of Food on the Pharmacokinetics of ZX008 (Fenfluramine Oral Solution): Results of a Single-dose, Two-period Crossover Study

Arnold Gammaitoni et al.

CLINICAL THERAPEUTICS (2018)

Add to Collection

Article

Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors

María Rodríguez-Muñoz et al.

Oncotarget (2018)

Add to Collection

Article Clinical Neurology

A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in Lennox-Gastaut syndrome

Lieven Lagae et al.

EPILEPSIA (2018)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacological Analysis of the Anti-epileptic Mechanisms of Fenfluramine in scn1a Mutant Zebrafish

Jo Sourbron et al.

FRONTIERS IN PHARMACOLOGY (2017)

Add to Collection

Review Medicine, General & Internal

Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population

An-Sofie Schoonjans et al.

CURRENT MEDICAL RESEARCH AND OPINION (2017)

Add to Collection

Article Clinical Neurology

Fenfluramine blocks low-Mg2+-induced epileptiform activity in rat entorhinal cortex

K Gentsch et al.

EPILEPSIA (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.